Add like
Add dislike
Add to saved papers

A New NLRP3 Inflammasome Inhibitor, Dioscin, Promotes Osteogenesis.

Small 2019 December 10
Refractory periapical periodontitis, which is a persistent infection after root canal treatment, still has no effective treatment. Its most common pathogen is Enterococcus faecalis. Here, the precursor of phytosteroids, dioscin, is introduced to fight against the inflammation induced by Enterococcus faecalis. The findings suggest that dioscin inhibits the nuclear transport of NF-κB and the expression of reactive oxygen species (ROS) induced by lipoteichoic acid from the Enterococcus faecalis. The decrease in mRNA and protein levels of NLRP3, Caspase-1, and IL-1β is observed in dioscin treated mouse macrophages. In the MC3T3-E1 cells, dioscin also promotes the expression of osteogenic-related factors, ALP, Runx2, and OCN. The increased formation of mineralized nodules after the application of dioscin further indicates that dioscin has the potential to promote osteogenesis. The above results suggest dioscin can be a potential root canal irrigation or root canal sealant for the treatment of refractory apical periodontitis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app